Quest Diagnostics Incorporated (NYSE:DGX) is processing substantially more laboratory work as hospitals and dialysis providers expand their testing relationships. Organic requisitions grew 11.9% year over year in the first half and 13.0% in the second quarter. Yet lower revenue per requisition and a narrower operating margin make the investment question more demanding: how much additional profit does that workload produce?
Quest Diagnostics Incorporated trades at approximately 20x forward P/E and 25x trailing P/E. Management’s 2026 reported EPS guidance of $9.97–$10.17 exceeds the $8.75 earned in 2025, supporting the earnings-growth direction behind the gap. Adjusted EPS guidance excludes costs including acquisition amortization and restructuring, so adjusted earnings growth should not be mistaken for an equivalent improvement in underlying operations.
Read the bull analysis here: Quest Diagnostics Incorporated (DGX): A Bull Case Theory
Quest Diagnostics Incorporated looks fairly valued at a premium to Labcorp Holdings Inc. (NYSE:LH), which trades at 16x forward P/E. Their 2026 adjusted EPS guidance midpoints imply approximately 13% and 11% growth, respectively. That modest growth lead needs stronger productivity to support the premium, while the peer’s biopharma business adds drug-development exposure. The network must keep turning broader patient access into profitable care without letting service costs consume additional revenue.
More Routine Work Changes the Economics
Quest Diagnostics Incorporated attributed roughly nine percentage points of second-quarter organic volume growth to new hospital and dialysis relationships. Those arrangements contain more routine testing, explaining much of the 2.8% decline in revenue per requisition. Excluding their mix effects, organic volume increased approximately 4%, and revenue per requisition rose about 3%, primarily because each requisition contained more tests. The aggregate decline therefore does not establish broad pricing erosion.
For Quest Diagnostics Incorporated, hospital outsourcing creates an opportunity to spread laboratory, collection and logistics costs across more specimens. Payer access helps channel patients into that network. However, routine testing must earn enough after staffing and supplies; additional throughput has little value if expenses rise just as quickly. Capacity expansion creates value when staffing investment pays for itself through higher utilization and lower unit costs.
The latest results show that hurdle at Quest Diagnostics Incorporated. Second-quarter adjusted operating margin declined to 16.5% from 16.9%. Incremental adjusted operating profit represented approximately 13% of incremental revenue, calculated from the reported changes, below the previous group margin. Automation and faster-growing advanced diagnostics could improve that return, while higher compensation and supply spending are already absorbing part of the growth.
Also read: 7 Most Undervalued Pot Stocks To Buy According To Analysts
Cash Generation Must Catch Up
Quest Diagnostics Incorporated generated $875 million of first-half operating cash flow and spent $252 million on capital projects. Subtracting capital expenditure leaves $623 million, compared with $633 million a year earlier. Billing and collection efficiency also weakened: days sales outstanding increased to 50 from 47 a year earlier. More earnings tied up in receivables leave less cash for debt reduction or distributions, making cash growth after reinvestment a necessary test of scale.
Quest Diagnostics Incorporated still guides to $11.95 billion–$12.05 billion of annual revenue. Its forward P/E was also approximately 20x on September 11, offering little evidence of a valuation reset over the available September comparison. Sustained demand and specialty testing support earnings growth, but the multiple requires better cash conversion. A second-quarter tax benefit of roughly $0.10 per diluted share also helped earnings without improving laboratory productivity.
Conclusion
Quest Diagnostics Incorporated is fairly valued at approximately 20x forward P/E. The mix explanation supports the customer franchise, while current incremental margins and cash generation leave the scale advantage unfinished. Recovering operating margins, faster collections, and durable specialty-testing growth would justify the premium. Persistently weaker cash conversion would make the cheaper peer more compelling, even if test volumes remain strong.
While we acknowledge the risk and potential of DGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Construction Partners (ROAD) Expands in Florida. Can a Stronger Local Network Lift Profits? and Ennis (EBF) Grows Sales but Earns Less. Are Legal Items Hiding a Better Business?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center